Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SPK-8011 AAV-mediated Hemophilia A therapy shows stability, durability

Publish date:: July 27, 2020

Key clinical point: SPK-8011 gene therapy for hemophilia A provides stable and durable factor VIII expression with no major safety concerns.

Major finding: FVIII activity was less than 2% before treatment and 5.2%-19.8% at 2 to 3.3 years after treatment.

Study details: A phase 1/2 study of 14 patients.

Disclosures: Spark Therapeutics sponsored the SPK-8011 study. Dr. George disclosed consulting and/or data safety monitoring board activity for Pfizer and AvroBio.

Citation:

George L et al. 2020 ISTH Congress, Abstract OC 03.5.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Hematology

Emotions, worse attention linked to pain-related health care use SCD,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Large cohort study: Bevacizumab safe, effective for severe HHT bleeds,

SPK-8011 AAV-mediated Hemophilia A therapy shows stability, durability,

Heavy menstrual bleeding difficult to control in young patients with inherited platelet disorders,